Advertisement

What Constitutes Therapeutic Success? The Interferons (1978–1998)

  • T. Pieters
Conference paper
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 5)

Abstract

Every so often, during the past 25 years, scientific claims of therapeutic accomplishment in the treatment of cancer have entered the public domain. The biographies of these experimental therapies seem to have a familiar pattern in common: implied claims for a cancer cure based on preliminary tests, exaggerated coverage in the media, high public expectations, widespread disappointment and loss of interest when the claims failed to materialize in large scale trials, researchers and administrators forced on the defensive. and finally there seems hardly any reason for continuation of research or for clinical application.

Keywords

Common Cold Hairy Cell Leukaemia Therapeutic Success Biological Response Modifier Professional Ambition 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pieters T (1993) Interferon and its first clinical trial: looking behind the scenes. Med Hist 37: 270–295PubMedCrossRefGoogle Scholar
  2. 2.
    Pieters T (1997) History of the development of the interferons: from test-tube to patient. In: Stuart-Harris R, Penny R (eds) The clinical applications of interferons. Chapman and Hall, London, pp 1–19Google Scholar
  3. 3.
    Krown S (1981) Prospects for the treatment of cancer with interferon. In: Burchenal J, Oettgen H (eds) Cancer; achievements, challenges, and prospects for the 1980’s. Grune and Stratton, New York, pp 367–379Google Scholar
  4. 4.
    Johnson R (1981) Interferon: cloudy but intriguing future. JAMA 245: 109–116PubMedCrossRefGoogle Scholar
  5. 5.
    Newmark P (1981) Interferon: decline and stall. Nature 291: 105–106PubMedCrossRefGoogle Scholar
  6. 6.
    Sun M (1981) Interferon: no magic bullet against cancer. Science 212: 141–142PubMedCrossRefGoogle Scholar
  7. 7.
    Fenyvesi C (1981) Beyond interferon. The Washington Post (14–6–1981), p 28Google Scholar
  8. 8.
    Powledge T (1984) Interferon on trial. Biotechnology 2: 214–228CrossRefGoogle Scholar
  9. 9.
    Editorial (1982) Million dollar cold cure. The Sunday Times (3–10–1982), pp 22 – 30Google Scholar
  10. 10.
    Scott GM, Phillpotts RJ, Wallace J et al (1982) Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia Coli. Lancet ii: 186–187Google Scholar
  11. 11.
    Alper J (1994) First there was interferon. The New York Times (18–111994), F 13Google Scholar
  12. 12.
    Wycke A (1987) Molecules and markets. The Economist (7–2–1987)Google Scholar
  13. 13.
    Vos R (1991) Drugs looking for diseases. Innovative drug research and the development of the beta blockers and the calcium antagonists. Kluwer Academic, AmsterdamGoogle Scholar
  14. 14.
    Oudshoorn N (1994) Beyond the natural body: archeology of sex hormones. Routledge, New YorkCrossRefGoogle Scholar
  15. 15.
    Editorial (1983) Interferon may help AIDS victims. New Scientist (3–11–1983)Google Scholar
  16. 16.
    Editorial (1981) Interferon tested on sclerosis. The New York Times (21–11–1981)Google Scholar
  17. 17.
    Finter N, Oldham RK (eds) (1985) Interferon, vol 4: in vivo and clinical studies. Elsevier, Amsterdam; (11–2–1983) update on interferon. News Service American Cancer Society, NCI Archives File no DC8301–006691Google Scholar
  18. 18.
    Intron A’, press information video tape produced by Schering-Plough in 1986 on the occasion of the market introduction of their interferon productGoogle Scholar
  19. 19.
    Quesada J, Hersh E, Gutterman J (1983) Hairy cell leukemia: induction of remission with alpha interferon. Blood 62: 207aGoogle Scholar
  20. 20.
    Quesada J, Reuben J, Manning J, Hersh E, Gutterman J (1984) Alpha interferon for induction of remission in hairy cell leukemia. N Engl J Med 310: 15–18PubMedCrossRefGoogle Scholar
  21. 21.
    Editorial (1983) Anticancer interferon available soon. Hospital Doctor (229–1983)Google Scholar
  22. 22.
    Petricciani J, Esber E, Hopps H, Attallah A (1984) Manufacture and safety of interferons in clinical research. In: Came P, Carter W (eds) Interferons and their applications. Springer, Berlin Heidelberg New York, pp 357–370CrossRefGoogle Scholar
  23. 23.
    Hage H (1986) Controlerende instanties moeten soepeler worden met interferon. Toegepaste Wetenschap TNO (1–10–1986)Google Scholar
  24. 24.
    Baron S, Dianzani F, Stanton G, Fleischmann W (eds) (1987) The Interferon system: a current review to 1987. The University of Texas Press, AustinGoogle Scholar
  25. 25.
    Baron S, Coppenhaver DH, Dianzane F (1992) Interferon: principles and medical applications. University of Texas Press, AustinGoogle Scholar
  26. 26.
    Wallis C (1985) What’s become of interferon? Time (1–6–1985)Google Scholar
  27. 27.
    Balkwill F (1985) Interferons: from common colds to cancer. New Scientist 105: 26–28Google Scholar
  28. 28.
    Balkwill F (1989) Cytokines in cancer therapy. Oxford University Press, OxfordGoogle Scholar
  29. 29.
    Gauci L (1990) Interferon drug development: a history truely consistent with the discovery process, paper presentation at the international meeting ‘from clone to clinic’, AmsterdamGoogle Scholar
  30. 30.
    Oldham RK (1985) Interferon: a model. In: Gresser I (ed) Interferon 6. Academic, London, pp 127–141Google Scholar
  31. 31.
    Barnes D (1987) Biologics gain influence in expanding NCI Program. Science 237: 848–850PubMedCrossRefGoogle Scholar
  32. 32.
    Foerstner A (1985) How we make our own wonder drugs. Chicago Tribune (20–1–1985)Google Scholar
  33. 33.
    Johnson HM, Bazer FW, Szente BE et al (1994) How interferons fight disease. Sci Am 270: 40–47CrossRefGoogle Scholar
  34. 34.
    Thomas HC, Cavalli F, Talpaz M (eds) (1987) Thirty years of interferon. Mediscript, London (Interferons today and tomorrow,vol 5 )Google Scholar
  35. 35.
    Kirchner H (ed) (1986) Update on interferons. Progress in oncology, vol 2. Mediscript, LondonGoogle Scholar
  36. 36.
    Kirchner H (ed) (1987) Update on interferons. Progress in virology, vol 1. Mediscript, LondonGoogle Scholar
  37. 37.
    Silver HK (ed) (1986) Interferons in cancer treatment. Medical Education Services, Mississauga, CanadaGoogle Scholar
  38. 38.
    Came PE, Carter WA (eds) (1984) Interferons and their applications. Springer, Berlin Heidelberg New YorkGoogle Scholar
  39. 39.
    Pinsky C (ed) (1986) Biological response modifiers. Semin Oncol 13: 131–227Google Scholar
  40. 40.
    Parkinson D (ed) (1994) The expanding role of interferon-alfa in the treatment of cancer. Semin Oncol 21: 1–37Google Scholar
  41. 41.
    Pocock S (1983) Clinical trials. Wiley, ChichesterGoogle Scholar
  42. 42.
    Van Dyck J (1995) Manufacturing babies and public consent. New York University Press, New York, p 124Google Scholar
  43. 43.
    Penny R (1990) Editorial. Interferons Cytokines 15: 3Google Scholar
  44. 44.
    Stuart-Harris R, Penny R (eds) (1997) Clinical applications of the interferons. Chapman and Hall, LondonGoogle Scholar
  45. 45.
    Shiell A, Salkeld G (1997) The economic aspects of interferon. In: Stuart-Harris R, Penny R (eds) The clinical applications of interferons. Chapman and Hall, London, pp 376–390Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • T. Pieters

There are no affiliations available

Personalised recommendations